@FiercePharma: Thursday's top story: Novo Nordisk recruiting 400 U.S. sales reps as growth decelerates. Article | Follow @FiercePharma
@EricPFierce: FDA has new plan to arrest drug shortages. Its ultimate solution is for drugmakers to improve quality. Story | Follow @EricPFierce
@CarlyHFierce: Once again, Bayer's new drugs power pharma sales upward. ICYMI yesterday | Follow @CarlyHFierce
> News media in Israel say that Erez Vigodman, a Teva Pharmaceutical Industries ($TEVA) director and CEO of Makhteshim Agan Industries, is favored to succeed Jeremy Leivn as CEO. Article
> Mylan ($MYL) says it has been sued by Teijin Pharma Limited and Takeda Pharmaceuticals in connection with its first-to-file application to make a generic version of Uloric. Release
> An official in the EU claims the cost of drugs in Ireland cannot be justified. Story
> Authorities in India have ruled against a shareholder of Zenotech Laboratories who challenged the acquisition of the Hyderabad-based company by Ranbaxy Laboratories. Story
@FierceMedDev: Sequenom vows to appeal court decision invalidating prenatal test patent. More | Follow @FierceMedDev
@MarkHFierce: PerkinElmer said the government shutdown could, in part, affect revenue projections for the year. ICYMI yesterday | Follow @MarkHFierce
@MichaelGFierce: OptiNose starts PhIII inhaler study for nasal polyps. Article | Follow @MichaelGFierce
> Boston Scientific closes $275M deal for Bard's electrophysiology arm. Story
> Gore begins long trek to pay back Bard in vascular graft patent ruling. Item
> Smith & Nephew reports improved Q3 and names new chairman. Article
Biotech News
@FierceBiotech: Popular yesterday: Feds launch probe of AstraZeneca's controversial late-stage Brilinta study. Article | Follow @FierceBiotech
@JohnCFierce: NovaQuest lands $459M fund for goal-line dealmaking--That's $1.2B for today. More | Follow @JohnCFierce
@DamianFierce: GlobeImmune pulls plug on $75M IPO despite still-bubbling market. Article | Follow @DamianFierce
@EmilyMFierce: Scripps Research scientists reach major milestone w/ HIV research, paving wave for new vaccine efforts. FierceBiotech Research story | Follow @EmilyMFierce
> Flailing Ariad swallows poison pill to fend off takeovers. More
> VC OrbiMed hauls in $735M fund in 'vibrant' time for biotech. News
> NovaQuest lands $459M fund for goal-line dealmaking. Story
And Finally... Piramal Enterprises has scratched an itch to broaden its OTC business with the acquisition of the skincare brand Caladryl in India from Valeant Pharmaceuticals ($VRX) for an undisclosed sum. Report